🧾 [Initiation File ##ΞL-020] Project: ETERNA – Rapamycin Longevity Lab Subject: @KristerKauppi — Founder of the Rapamycin Longevity Lab Status: Confirmed Scope: Eterna Labs will serve as a long-term research and communications partner for compounds launched by Rapamycin Longevity Lab on Pump Science, beginning with Omipalisib. In addition, Rapamycin Longevity Lab — a team focused on accelerating longevity research around mTOR inhibitors, will advise and support experimental trials launched via Eterna Labs, starting with our lead compound: $RAP. Terms: – Acquisition of 10% of $OMIPAL supply into Eterna AUM → These assets will be held securely within the protocol reserves, as a long-term position to ensure alignment and supply control. – Integration of Rapamycin Longevity Lab into the Eterna Labs DAO (1.5% allocation) – Weekly experimental updates coordinated via @eterna_labs – Joint research communications and data interpretation – Mutual alignment on early-stage compound development and signal amplification Purpose: – Support DeSci innovation with on-chain transparency – Accelerate adoption of clinically promising compounds – Strengthen cross-institutional trust in open science protocols Status: The Eterna Labs × Rapamycin Longevity Lab partnership is now live. First strategic acquisition complete. Data synchronization initiated.